Current Illinois CancerCare Clinical Trials

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)

Study Number: GO41767

Study Summary:
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized 1:1 to receive one of the following treatment regimens during induction phase:-

Arm A: Tiragolumab plus atezolizumab and CE
Arm B: Placebo plus atezolizumab and CE
Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).

Status: Open

Open in Bloomington, Galesburg, Ottawa, Pekin, Peoria and Peru

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611
  • Amanda , 309-243-3663,
  • Jessica, 309-243-3615,

Study Link

« Search Again
WordPress PopUp Plugin